{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T15:25:49Z","timestamp":1785079549460,"version":"3.55.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gastric cancer (GC) is the fifth most common malignant tumor worldwide. The peritoneum is a common site of metastasis in advanced GC, and patients with gastric cancer peritoneal metastasis (GCPM) have a very low 5-year survival rate. Systemic therapy has limited efficacy for peritoneal metastases, and early diagnosis is difficult. In this paper, we analyzed the GCPM-related literature by bibliometric methods, aiming to identify the research hotspots and trends and to provide a basis for clinical practice and research planning.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Based on the Web of Science Core Collection database (WoSCC), we screened the GCPM-related literature published from 2004 to 2024. Countries, institutions, authors, journals, and keywords were analyzed and visualized by tools such as CiteSpace, VOSviewer, Scimago Graphica, RStudio, and the Bibliometrix package.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>A total of 2416 publications were included in this study. The growth rate of GCPM publications is positive until 2021, with a slowdown in the near future. Japan dominated the research output (842 publications), followed by China (748 publications) and the United States (268 publications). Japanese-affiliated organizations and researchers are extremely productive in the field of GCPM. The most frequently cited document was Japanese gastric cancer treatment guidelines 2014 (ver. 4) (citations = 2076). Research focuses on four major clusters: (1) molecular mechanisms of GCPM; (2) prognosis of GCPM; (3) chemotherapy of GCPM; and (4) intraperitoneal treatment of GCPM. Emerging trends include key pathways of GCPM, artificial intelligence (AI) and multi-omics-driven early diagnosis, novel intraperitoneal therapeutic modalities, and immunologic\/targeted drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Japan is a leader in GCPM research. Recently, the focus of GCPM research has shifted from basic treatment to precision and personalized treatment through the integration of molecular mechanisms, novel intraperitoneal therapeutic modalities, and AI technologies. Current challenges include the lack of standardized validation systems for emerging technologies and regional differences in clinical practice. In the future, there is a need to promote global collaborative trials and optimization of multimodality therapy. The results of this study provide a key direction and systematic basis for future exploration of GCPM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1583364","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:10:15Z","timestamp":1748578215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Two decades of progress in gastric cancer peritoneal metastasis: a bibliometric perspective on molecular mechanisms and therapeutic innovations"],"prefix":"10.3389","volume":"15","author":[{"given":"Jin","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.045","article-title":"Burden of gastric cancer","volume":"18","author":"Thrift","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10740","article-title":"Metastatic spread in patients with gastric cancer","volume":"7","author":"Riihim\u00e4ki","year":"2016","journal-title":"Oncotarget"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i39.6037","article-title":"Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology","volume":"26","author":"Verstegen","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v134.3","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2022.01.024","article-title":"Patterns of gastric cancer metastasis in the United States","volume":"224","author":"Sirody","year":"2022","journal-title":"Am J Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2022.11.011","article-title":"Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study","volume":"179","author":"Kroese","year":"2023","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0799-9","article-title":"Validation of the prognostic impact of the new tumor-node-metastasis clinical staging in patients with gastric cancer","volume":"22","author":"Bando","year":"2019","journal-title":"Gastric Cancer"},{"key":"B9","article-title":"Gastric cancer cells in peritoneal lavage fluid: A systematic review comparing cytological with molecular detection for diagnosis of peritoneal metastases and prediction of peritoneal recurrences","volume":"38","author":"Virgilio","year":"2018","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.56735","article-title":"Progress of gastric cancer surgery in the era of precision medicine","volume":"17","author":"Wang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2015.35.issue-6","article-title":"A descriptive and historical review of bibliometrics with applications to medical sciences","volume":"35","author":"Thompson","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.joi.2018.03.005","article-title":"Examining the usage, citation, and diffusion patterns of bibliometric mapping software: A comparative study of three tools","volume":"12","author":"Pan","year":"2018","journal-title":"J informetrics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"Van Eck","year":"2010","journal-title":"scientometrics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.3390\/ijms20122870","article-title":"Roles of E-cadherin and noncoding RNAs in the epithelial-mesenchymal transition and progression in gastric cancer","volume":"20","author":"Bure","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2024.08.007","article-title":"Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases","volume":"167","author":"Zhao","year":"2024","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00240-6","article-title":"Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities","volume":"2","author":"Tanaka","year":"2021","journal-title":"Nat Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.11.008","article-title":"Integrin \u03b15 mediates cancer cell-fibroblast adhesion and peritoneal dissemination of diffuse-type gastric carcinoma","volume":"526","author":"Miyamoto","year":"2022","journal-title":"Cancer Lett"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2200546","DOI":"10.1002\/advs.202200546","article-title":"Succinylation inhibits the enzymatic hydrolysis of the extracellular matrix protein fibrillin 1 and promotes gastric cancer progression","volume":"9","author":"Wang","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1756-9966-29-139","article-title":"Induction of gastric cancer cell adhesion through transforming growth factor-beta1-mediated peritoneal fibrosis","volume":"29","author":"Lv","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02891-4","article-title":"Tumor-mesothelium HOXA11-PDGF BB\/TGF \u03b21-miR-181a-5p-Egr1 feedforward amplifier circuity propels mesothelial fibrosis and peritoneal metastasis of gastric cancer","volume":"43","author":"Wang","year":"2024","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/gutjnl-2018-318070","article-title":"Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response","volume":"69","author":"Wang","year":"2020","journal-title":"Gut"},{"key":"B25","doi-asserted-by":"publisher","first-page":"108779","DOI":"10.1016\/j.celrep.2021.108779","article-title":"Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination","volume":"34","author":"Yasuda","year":"2021","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41419-022-04747-3","article-title":"RBMS1 promotes gastric cancer metastasis through autocrine IL-6\/JAK2\/STAT3 signaling","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-020-01208-3","article-title":"Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p\/HUR\/VEGF axis and suppressing HSP90 degradation","volume":"19","author":"Xie","year":"2020","journal-title":"Mol Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2300961","DOI":"10.1002\/advs.202300961","article-title":"Accurate and rapid detection of peritoneal metastasis from gastric cancer by AI-assisted stimulated raman molecular cytology","volume":"10","author":"Chen","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz001","article-title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","volume":"30","author":"Dong","year":"2019","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2032269","DOI":"10.1001\/jamanetworkopen.2020.32269","article-title":"Noninvasive prediction of occult peritoneal metastasis in gastric cancer using deep learning","volume":"4","author":"Jiang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(22)00040-1","article-title":"Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study","volume":"4","author":"Jiang","year":"2022","journal-title":"Lancet Digit Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e2411490","DOI":"10.1002\/advs.202411490","article-title":"Multimodal artificial intelligence-based virtual biopsy for diagnosing abdominal lavage cytology-positive gastric cancer","volume":"12","author":"Ding","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.v27.22","article-title":"Gastric cancer peritoneal metastasis related signature predicts prognosis and sensitivity to immunotherapy in gastric cancer","volume":"27","author":"Sun","year":"2023","journal-title":"J Cell Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00432-024-05707-4","article-title":"Dynamic change in the peritoneal cancer index based on CT after chemotherapy in the overall survival prediction of gastric cancer patients with peritoneal metastasis","volume":"150","author":"Wei","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.550526","article-title":"An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i43.6451","article-title":"Application of preoperative artificial neural network based on blood biomarkers and clinicopathological parameters for predicting long-term survival of patients with gastric cancer","volume":"25","author":"Que","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): A propensity score analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial","volume":"42","author":"Rau","year":"2024","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000457","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: a systematic review and meta-analysis","volume":"109","author":"Patel","year":"2023","journal-title":"Int J Surg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-016-0662-9","article-title":"Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis","volume":"20","author":"Kobayashi","year":"2017","journal-title":"Gastric Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.05.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"103846","DOI":"10.1016\/j.critrevonc.2022.103846","article-title":"Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for gastric cancer with peritoneal metastases: A systematic review by the PIPAC UK collaborative","volume":"180","author":"Case","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"103681","DOI":"10.1016\/j.esmoop.2024.103681","article-title":"Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes","volume":"9","author":"Sundar","year":"2024","journal-title":"ESMO Open"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1186\/s12885-023-11549-z","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study","volume":"23","author":"Luksta","year":"2023","journal-title":"BMC Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.905922","article-title":"Efficacy and safety of conversion therapy by intraperitoneal and intravenous paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis: A prospective phase II study","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1186\/s12885-021-09027-5","article-title":"Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases","volume":"21","author":"Shi","year":"2021","journal-title":"BMC Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-023-01452-8","article-title":"Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study","volume":"27","author":"Yang","year":"2024","journal-title":"Gastric Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-21-375","article-title":"Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective study","volume":"12","author":"Ding","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41392-022-01198-2","article-title":"A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis","volume":"7","author":"Ma","year":"2022","journal-title":"Signal Transduct Target Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1583364\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:10:16Z","timestamp":1748578216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1583364\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":62,"alternative-id":["10.3389\/fonc.2025.1583364"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1583364","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"article-number":"1583364"}}